Document Detail


The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
MedLine Citation:
PMID:  18266209     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
JAK2V617F-positive patients with essential thrombocythemia, as opposed to their mutation-negative counterparts, require lower doses of hydroxyurea (HU) for control of their platelet count. In the current study, we looked for predictors of HU response in 69 patients with primary myelofibrosis (PMF) and 56 with polycythemia vera (PV). JAK2V617F analysis was performed on bone marrow-derived DNA obtained at or near the time of diagnosis. HU response in PMF was associated with a shorter disease duration (P = 0.008), absence of previous therapy (P = 0.01), older age at diagnosis (P = 0.009), and presence of JAK2V617F (P = 0.02). On multivariable analysis, only the latter retained its significance (48% vs. 8% response in mutation positive vs. negative cases). In PV, JAK2V617F allele burden correlated directly with HU response (P = 0.05) and inversely with daily HU dose in responding patients (P = 0.02). The current study suggests that JAK2V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV.
Authors:
Shireen Sirhan; Terra L Lasho; Curtis A Hanson; Ruben A Mesa; Animesh Pardanani; Ayalew Tefferi
Related Documents :
17034039 - Needle electromyography of the rectus abdominis in patients with amyotrophic lateral sc...
8596139 - Hla-dr1, dr4, and drb1 disease related subtypes in rheumatoid arthritis. association wi...
20496429 - Collaboration with patients in the design of patient-reported outcome measures: capturi...
15693109 - Is there a need for new therapies for rheumatoid arthritis?
11128659 - Mycoplasma fermentans in rheumatoid arthritis and other inflammatory arthritides.
10990219 - Hla-drb1 genes, rheumatoid factor, and elevated c-reactive protein: independent risk fa...
6631029 - The protean manifestations of legionnaires' disease.
8526619 - Ball valve (smeloff-cutter) aortic valve replacement without anticoagulation.
16940319 - Spectrum of clinical features and type iv collagen alpha-chain distribution in chinese ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of hematology     Volume:  83     ISSN:  1096-8652     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-22     Completed Date:  2008-06-10     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  363-5     Citation Subset:  IM    
Copyright Information:
Copyright 2008 Wiley-Liss, Inc.
Affiliation:
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age Factors
Aged
Alleles
Cohort Studies
DNA Mutational Analysis
Drug Resistance / genetics
Female
Humans
Hydroxyurea / administration & dosage,  therapeutic use*
Janus Kinase 2 / genetics*
Male
Middle Aged
Mutation, Missense*
Platelet Count
Point Mutation*
Polycythemia Vera / drug therapy,  enzymology*,  genetics
Primary Myelofibrosis / drug therapy,  enzymology*,  genetics
Treatment Outcome
Chemical
Reg. No./Substance:
127-07-1/Hydroxyurea; EC 2.7.1.112/JAK2 protein, human; EC 2.7.10.1/Janus Kinase 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong Kong.
Next Document:  Commonly cited website quality criteria are not effective at identifying inaccurate online informati...